Afamelanotide is a less widely discussed example of an FDA-approved peptide drug, developed for a rare genetic condition rather than for weight loss or metabolic disease. This guide explains what it is, how it works, and what the evidence behind its approval actually showed.

What It Is

Afamelanotide is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring hormone involved in regulating skin pigmentation. It is marketed under the brand name Scenesse by the Australian company Clinuvel Pharmaceuticals, delivered as a subcutaneous implant rather than a self-administered injection or pill.

Regulatory Status

The FDA approved afamelanotide (Scenesse) on October 8, 2019, for the treatment of adults with erythropoietic protoporphyria (EPP) who have a history of phototoxic reactions, meaning painful skin reactions triggered by light exposure. It had previously been approved in the European Union in 2014. This makes afamelanotide one of a relatively small number of therapeutic peptides with a full FDA approval for a specific, defined indication, distinct from the much larger number of peptides sold as unapproved “research use only” products.

What Erythropoietic Protoporphyria Is

EPP is a rare, inherited metabolic disorder in which the body cannot properly process protoporphyrin, a molecule involved in making heme (a component of hemoglobin). This causes protoporphyrin to build up in the skin and blood, making skin extremely sensitive to visible light and provoking severe, often disproportionate, pain and burning on light-exposed skin, sometimes within minutes of sun exposure. It's a lifelong condition with no cure, and until Scenesse's approval, patients had few options beyond strict light avoidance.

How It Works

Afamelanotide works as a melanocortin-1 receptor (MC1R) agonist, meaning it activates the same receptor responsible for producing eumelanin, the skin pigment that provides some natural protection against light-related damage. Unlike a tan from sun exposure, afamelanotide increases eumelanin production independent of light exposure itself, which is the basis for its use in a condition where light exposure is exactly what needs to be minimized.

What the Clinical Trials Showed

The FDA approval was supported by two placebo-controlled trials. In the larger trial, 93 patients receiving afamelanotide implants spent a median of 64 hours in direct sunlight between 10 a.m. and 6 p.m. without pain over 180 days, compared with a median of 41 hours for the placebo group. In a second, smaller trial of 74 patients over 270 days, treated patients spent a median of 6 pain-free hours outdoors in predominantly direct sunlight between 10 a.m. and 3 p.m., compared with 0.75 hours for placebo. The drug is administered as an implant roughly every two months, and the most commonly reported side effects in trials included implant-site reactions, nausea, throat pain, cough, fatigue, increased skin pigmentation, dizziness, and respiratory tract infections.

Why This Peptide Is Worth Knowing About

Afamelanotide is a useful reference point for readers trying to understand what a genuine, evidence-backed peptide drug approval looks like: a specific, well-defined rare disease, placebo-controlled human trials with clearly defined and measured outcomes, an established mechanism of action, and an FDA-reviewed label spelling out dosing, administration, and side effects. That stands in sharp contrast to peptides like the melanotan compounds sold online for tanning, which share some chemical lineage with afamelanotide but have none of this same trial evidence or regulatory oversight behind them, as covered in this site's guide to Melanotan II.

The Bottom Line

Afamelanotide (Scenesse) is an FDA-approved treatment for a specific rare disease, administered under medical supervision as an implant, not a self-injected compound. It is not indicated for general tanning, cosmetic skin darkening, or any use outside erythropoietic protoporphyria, and anyone considering it should do so only through a physician managing that diagnosis.